Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Purchases of Investments
Cash used to buy marketable securities and other investments.
Sionna Therapeutics, Inc.NASDAQ: SION
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments declines year over year
Q1 FY2026 purchases of investments of $25.33M (cash outflow) fell 85.2% year over year, behind the -22.5% change in trailing-twelve-month purchases of investments. Sequentially, it fell 40.9% from the prior quarter. Over 3 fiscal years it compounded at +100.4% a year.
Context
- Purchases of investments grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -85.2% toward the trailing-twelve-month pace of -22.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (325.03M) USD
- Year-over-year change
- -77.8%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (325.03M) | -77.8% |
| FY2024 | 2024-12-31 | (182.84M) | -677.0% |
| FY2023 | 2023-12-31 | (23.53M) | +41.7% |
| FY2022 | 2022-12-31 | (40.39M) | — |
Purchases of Investments vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 purchases of investments of $178.76M is the 8th largest of the 11 companies compared; the peer median is $268.71M.
- Its year-over-year change of -22.5% is the 7th highest of 10, against a peer median of +22.1%.
- Over three fiscal years its annual growth of +100.4% compares with a peer median of +27.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $744.36M | +50.0% | -16.6% | 1097.0% | |
| LTM Sep 2026 | $579.46M | +26.3% | +26.7% | 517377.7% | |
| LTM Mar 2026 | $446.68M | -32.7% | +33.8% | 2066.7% | |
| LTM Jun 2026 | $431.81M | -22.1% | +27.9% | — | |
| LTM Sep 2026 | $302.18M | +53.3% | — | — | |
| LTM Mar 2026 | $235.25M | +22.1% | +63.2% | 55.0% | |
| LTM Mar 2026 | $211.3M | — | — | 1056.5% | |
| LTM Mar 2026 | $178.76M | -22.5% | +100.4% | — | |
| LTM Jun 2026 | $138.24M | -79.7% | +0.4% | — | |
| LTM Sep 2026 | $117.65M | -39.1% | +68.9% | 44.2% | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding SION) | $268.71M | +22.1% | +27.9% | 1056.5% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.